Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever
Crimean-Congo hemorrhagic fever (CCHF) is endemic in Africa, Asia, southeast Europe, and the Middle East. The case fatality rate is 30–50%. Studies on pathophysiology and treatment of CCHF have been hampered by the lack of an appropriate animal model. We have employed CCHF virus-infected transgenic...
Main Authors: | Oestereich, Lisa, Rieger, Toni, Neumann, Melanie, Bernreuther, Christian, Lehmann, Maria, Krasemann, Susanne, Wurr, Stephanie, Emmerich, Petra, de Lamballerie, Xavier, Ölschläger, Stephan, Günther, Stephan |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006714/ |
Similar Items
-
Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever
by: Oestereich, Lisa, et al.
Published: (2016) -
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
by: Yamada, Kentaro, et al.
Published: (2016) -
Bradycardia in a patient with Crimean-Congo hemorrhagic fever related to ribavirin treatment
by: Burcu Uysal & Gökhan Metan
Published: (2012-09-01) -
Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever
by: Salehi, Hassan, et al.
Published: (2013) -
Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever
by: Mendenhall, Michelle, et al.
Published: (2011)